The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 21: 2768 - 2774

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.21.013

Clinical Research

Clinical analysis of 32 cases of Alport syndrome with predominant COL4A5 gene mutation

  • Yi′nan LIU ,
  • Yongtao ZHANG ,
  • Shaowei YU ,
  • Lirong LUO ,
  • Yihui HUANG ,
  • Shengyou YU ,
  • Li YU
Expand
  • Department of Pediatrics，Guangzhou Red Cross Hospital of Ji′nan University，Guangzhou 510220，China

Received date: 2023-08-10

  Online published: 2023-12-19

Fold

Abstract

Objective To analyze the clinical phenotypes and mutation types of children with X-linked Alport syndrome （XLAS） with mutations in COL4A5 gene， and to explore the relationship between children with XLAS and nephrotic syndrome nephritic type. Methods Thirty-two children with COL4A5 gene mutations detected by second-generation sequencing and finally diagnosed with Alport syndrome at Guangzhou Red Cross Hospital affiliated with Jinan University and the First People's Hospital of Guangzhou between April 2016 and April 2023 were included， and their clinicopathological features and gene mutation characteristics were retrospectively analyzed. Results The mean age of onset of disease in children with XLAS was （3.68 ± 2.07） years old， the mean age at diagnosis （6.56 ± 2.95） years old， 12 cases （37.5%） started with isolated hematuria， 8 cases （25%） started with hematuria and proteinuria， 12 cases （37.5%） started with nephrotic syndrome nephritic phenotype， and the positive family history of the children was found in 11 cases （34.4%）， ocular lesions were found in 3 cases （9.37%）， ear lesions in 6 cases （18.75%）， and 7 cases （21.87%） were found to have developed chronic kidney disease （CKD） in the later follow-up. 21 children underwent renal tissue puncture biopsy， and electron microscopy showed thinning of the basement membrane （diffuse or segmental） in 13 cases （61.9%）， and uneven thickness of the basement membrane in 8 cases （38.09%）； light microscopy showed thinning of the basement membrane in 13 cases （61.9%）； light microscopy showed thinning of the basement membrane in 8 cases （38.09%）； and light microscopy showed thinning of the basement membrane in 3 cases （11.5%）. （38.09%）； light microscopy： focal segmental glomerulosclerosis （FSGS） in 2 cases （9.52%）， mesangial proliferative glomerulonephritis （Ms PGN） in 11 cases （52.38%）， and minimal change disease （MCD） in 8 cases （38.09%）. The type of mutation was categorized as missense mutation in 12 cases （37.5%）， shear site mutation in 9 cases （28.12%）， nonsense mutation in 6 cases （18.75%）， deletion mutation in 3 cases （9.37%）， and code shift mutation in 2 cases （6.25%）. Genetic mutations were present in 22 cases （68.75%）； spontaneous mutations were present in 10 cases （27.02%）. Conclusions Children with XLAS have atypical clinical manifestations and pathologic features in the early stage of the disease， and the progress is slow， and some of them are easy to be misdiagnosed as nephrotic syndrome nephritis type in the early stage， so it is important to improve the genetic test for this disease as early as possible， and to make reasonable drug choices to predict the prognosis scientifically.

Key words： COL4A5; Alport syndrome; nephrotic syndrome nephritic type; clinical

Cite this article

Yi′nan LIU , Yongtao ZHANG , Shaowei YU , Lirong LUO , Yihui HUANG , Shengyou YU , Li YU . Clinical analysis of 32 cases of Alport syndrome with predominant COL4A5 gene mutation[J]. The Journal of Practical Medicine, 2023 , 39(21) : 2768 -2774 . DOI: 10.3969/j.issn.1006-5725.2023.21.013

References

1 Alport综合征协作组，国家肾脏疾病临床医学研究中心，北京医学会罕见病分会. Alport综合征诊治专家共识（2023版）［J］. 中华医学杂志，2023， 103（20）： 1507-1525.
2 SAVIGE J， STOREY H， WATSON E，et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome： refining the ACMG criteria［J］. Eur J Hum Genet， 2021，29（8）：1186-1197.
3 KASHTAN C E， DING J， GAROSI G，et al. Alport syndrome： a unified classification of genetic disorders of collagen IV α345： a position paper of the Alport Syndrome Classification Working Group［J］. Kidney Int， 2018，93（5）：1045-1051.
4 NAYLRO R W， MORAIS MRPT， LENNON R，et al. Complexities of the glomerular basement membrane［J］. Nat Rev Nephrol， 2021，17（2）：112-127.
5 GIBSON J T， SADEGHI-ALAVIJEH O， GALE D P，et al. Pathogenicity of missense variants affecting the collagen IV α5 carboxy non-collagenous domain in X-linked Alport syndrome［J］. Sci Rep， 2022，12（1）：11257.
6 SAVIGE J. Heterozygous Pathogenic COL4A3 and COL4A4 Variants （autosomal dominant alport syndrome） are common， and not typically associated with end-stage kidney failure， hearing loss， or ocular abnormalities［J］. Kidney Int Rep， 2022，7（9）：1933-1938.
7 ZHOU L， XI B， XU Y，et al. Clinical， histological and molecular characteristics of Alport syndrome in Chinese children［J］. J Nephrol， 2023，36： 1415-1423.
8 SAVIGE J， LIPSKA-ZIETKIEWICZ B S， WATSON E，et al.Guidelines for genetic testing and management of Alport syndrome［J］. Clin J Am Soc Nephrol， 2022，17（1）：143-154.
9 KAMENETSKY I， RANGAYYAN R M， BENEDIKTSSON H，et al. Analysis of the glomerular basement membrane in images of renal biopsies using the split-and-merge method： a pilot study［J］. J Digit Imaging， 2010，23（4）：463-474.
10 HERTZ J M， THOMASSEN M， STOREY H，et al. Clinical utility gene card for： Alport syndrome-update 2014［J］. Eur J Hum Genet， 2015，23（9）. doi： 10.1038/ejhg.2014.254 .
11 谭俊杰，张瑶，于生友，等. 以激素耐药型肾病综合征起病的Alport综合征15例临床分析［J］. 中国实用儿科杂志，2021，36（2）：125-129.
12 NOZU K， NAKANISHI K，ABE Y，et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome［J］. Clin Exp Nephrol， 2019，23（2）：158-168.
13 SAVIGE J， HUANG M， CROOS DABRERA M S，et al. Genotype-phenotype correlations for pathogenic COL4A3-COL4A5 variants in x-linked， autosomal recessive， and autosomal dominant Alport syndrome［J］. Front Med （Lausanne）， 2022，9：865034.
14 TAN R， COLVILLE D， WANG Y Y，et al. Alport retinopathy results from "severe" COL4A5 mutations and predicts early renal failure［J］. Clin J Am Soc Nephrol， 2010，5（1）：34-38.
15 BEKHEIRNIA M R， REED B， GREGORY M C，et al. Genotype-phenotype correlation in X-linked Alport syndrome［J］. J Am Soc Nephrol， 2010，21（5）：876-883.
16 MIGEON B R. X inactivation， female mosaicism， and sex differences in renal diseases［J］. J Am Soc Nephrol， 2008，19（11）：2052-2059.
17 JAIS J P， KNEBELMANN B， GIATRAS I，et al. X-linked Alport syndrome： natural history and genotype-phenotype correlations in girls and women belonging to 195 families： a "European Community Alport Syndrome Concerted Action" study［J］. J Am Soc Nephrol， 2003，14（10）：2603-2610.
18 GIBSON J T， DE GOOYER M， HUANG M，et al. A systematic review of pathogenic COL4A5 variants and proteinuria in women and girls with X-linked Alport syndrome［J］. Kidney Int Rep， 2022，7（11）：2454-2461.
19 党西强，曹艳，易著文，等. 313例6岁以下小儿肾脏疾病病理特点及其与临床表现的关系［J］. 中南大学学报（医学版），2008，33（3）：227-232.
20 陈燕贞，孙良忠，王海燕，等. 儿童Alport综合征的临床和病理特征及误诊：91例回顾性分析［J］. 中国当代儿科杂志，2017，19（4）：371-375.
Options
Outlines

/

〈 〉